Can-Fite BioPharma Showcases Advanced Drug Pipeline at Noble Capital Markets Emerging Growth Conference
Can-Fite BioPharma Ltd. will present its advanced drug development pipeline, including a Phase III liver cancer trial, at the Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference on December 3rd, 2025, in Boca Raton, Florida. CEO Motti Farbstein will present and meet with investors. A webcast will be available on the company's website. The news was originally published by Can-Fite BioPharma via GlobeNewswire.
Can-Fite BioPharma Ltd. will present the latest developments in its advanced stage drug development pipeline, including a Phase III liver cancer trial, at Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference. The event will take place on Wednesday, December 3rd, 2025, at Florida Atlantic University’s Executive Education Complex in Boca Raton, Florida. CEO Motti Farbstein will deliver the presentation and hold one-on-one meetings with investors. A high-definition video webcast of the presentation will be available the following day on the company’s website and related platforms. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9592681-en) on November 26, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
